Abstract: Isolated heparin or heparan sulphate oligosaccharide fragments having a chain length of at least 10 saccharides and no more than 50 saccharides, which are capable of binding BMP2, are disclosed. Also disclosed is the use of the same heparin or heparan sulphate oligosaccharide fragments in kits and pharmaceutical compositions, and the use of the same heparan sulphate oligosaccharide fragments in the repair and/or regeneration of connective tissue and bones, and the treatment of wounds.

Abstract: A trace element solution comprises at least the following metals zinc directly and/or indirectly from Zn-EDTA and/or Zn oxide; manganese directly and/or indirectly from Mn-EDTA and/or manganese carbonate; copper directly and/or indirectly from Cu-EDTA and/or copper oxide and/or copper sulphate, and/or copper carbonate; selenium derived directly and/or indirectly from Na2SeO4 and/or Na2SeO3. The metals are present in a solution of water, chlorocresol and/or benzyl alcohol, at a concentration of metals of at least 95 mg/ml. The pH of the trace element solution adjusted by means of 30% NaOH in an injectable trace element solution that is visually stable.

Abstract: A trace element solution comprises at least the following metals zinc directly and/or indirectly from Zn-EDTA and/or Zn oxide; manganese directly and/or indirectly from Mn-EDTA and/or manganese carbonate; copper directly and/or indirectly from Cu-EDTA and/or copper oxide and/or copper sulphate, and/or copper carbonate; selenium derived directly and/or indirectly from Na2SeO4 and/or Na2SeO3. The metals are present in a solution of water, chlorocresol and/or benzyl alcohol, at a concentration of metals of at least 95 mg/ml. The pH of the trace element solution adjusted by means of 30% NaOH in an injectable trace element solution that is visually stable.

Abstract: Isolated heparin or heparan sulphate oligosaccharide fragments having a chain length of at least 10 saccharides and no more than 50 saccharides, which are capable of binding BMP2, are disclosed. Also disclosed is the use of the same heparin or heparan sulphate oligosaccharide fragments in kits and pharmaceutical compositions, and the use of the same heparan sulphate oligosaccharide fragments in the repair and/or regeneration of connective tissue and bones, and the treatment of wounds.

Abstract: The present invention provides the use of lipocalin 2 (LCN2) as a biomarker for IL-17 mediated diseases and for monitoring the response of a patient to anti-IL-17 therapy.

Abstract: The wheel lift for changing tire on a vehicle (hereinafter wheel lift) is a mechanical structure. The wheel lift forms a jack used to elevate a vehicle such that the wheel of the vehicle can be removed and replaced. The wheel lift is a portable structure. The wheel lift is a rolling structure. The wheel lift is a non-Euclidean structure such that the wheel targeted for replacement can roll onto the wheel lift. The wheel lift comprises a pedestal, a jack structure, and a wheel rack. The jack structure attaches the wheel rack to the pedestal. The span of the length of the jack structure in the vertical direction adjusts such that the jack structure controls the elevation of the wheel rack above the supporting surface. The wheel rack receives and supports the wheel targeted for replacement.

Abstract: Isolated heparin or heparan sulphate oligosaccharide fragments having a chain length of at least 10 saccharides and no more than 50 saccharides, which are capable of binding BMP2, are disclosed. Also disclosed is the use of the same heparin or heparan sulphate oligosaccharide fragments in kits and pharmaceutical compositions, and the use of the same heparan sulphate oligosaccharide fragments in the repair and/or regeneration of connective tissue and bones, and the treatment of wounds.

Abstract: In various embodiments, the present disclosure relates generally to gaming systems and methods providing a live craps game and a plurality of electronic gaming machines that facilitate participation in the live craps game.

Abstract: A trace element solution comprises at least the following metals: zinc; manganese; selenium; and copper; and which comprises Vitamin B12. The solution furthermore comprises butaphosphan to stabilize the Vitamin B12 and the inclusion of butaphosphan may have synergistic activity with the minerals.

Abstract: Isolated heparin or heparan sulphate oligosaccharide fragments having a chain length of at least 10 saccharides and no more than 50 saccharides, which are capable of binding BMP2, are disclosed. Also disclosed is the use of the same heparin or heparan sulphate oligosaccharide fragments in kits and pharmaceutical compositions, and the use of the same heparan sulphate oligosaccharide fragments in the repair and/or regeneration of connective tissue and bones, and the treatment of wounds.

Abstract: A trace element solution comprises at least the following metals: zinc; manganese; selenium; and copper; and which comprises a concentration of the metals of at least 90 mg/ml. The solution may comprise the following concentrations: at least 60 mg/ml zinc; at least 10 mg/ml manganese; at least 5 mg/ml selenium; and at least 15 mg/ml copper. The solution may comprise chromium, iodine and chromium.

Abstract: A trace element solution comprises at least the following metals: zinc; manganese; selenium; and copper; and which comprises a concentration of the metals of at least 90 mg/ml. The solution may comprise the following concentrations: at least 60 mg/ml zinc; at least 10 mg/ml manganese; at least 5 mg/ml selenium; and at least 15 mg/ml copper. The solution may comprise chromium, iodine and chromium.

Abstract: A trace element solution comprises at least the following metals zinc directly and/or indirectly from Zn-EDTA and/or Zn oxide; manganese directly and/or indirectly from Mn-EDTA and/or manganese carbonate; copper directly and/or indirectly from Cu-EDTA and/or copper oxide and/or copper sulphate, and/or copper carbonate; selenium derived directly and/or indirectly from Na2SeO4 and/or Na2SeO3. The metals are present in a solution of water, chlorocresol and/or benzyl alcohol, at a concentration of metals of at least 95 mg/ml. The pH of the trace element solution adjusted by means of 30% NaOH in an injectable trace element solution that is visually stable.

Abstract: A trace element solution comprises selenium, zinc, manganese and copper at a concentration of at least 60 mg/ml. The solution may further comprise at least one compound selected from the group comprising iodine, potassium iodide, sodium iodide, zinc oxide, manganese sulphate, sodium selenite, copper carbonate, sodium carbonate, anhydrous disodium EDTA and sodium hydroxide.

Abstract: The invention discloses a trace element solution, which comprises at least the following metals: at least 65 mg/ml zinc directly and/or indirectly from mineral EDTA chelate(s) and/or Zn Oxide; at least 10 mg/ml manganese directly and/or indirectly from mineral EDTA chelate(s) and/or Mn carbonate; at least 15 mg/ml copper directly and/or indirectly from mineral EDTA chelate(s) and/or copper sulphate and/or copper oxide and/or carbonate; and at least 5 mg/ml selenium. The trace element solution comprises at least the following: at least 65 mg/ml zinc derived directly and/or indirectly from ZN-EDTA and/or Zn Oxide; at least 10 mg/ml manganese derived directly and/or indirectly from Mn-EDTA and/or Mn carbonate; at least 15 mg/ml copper derived directly and/or indirectly from Cu-EDTA and/or copper oxide and/or copper sulphate and/or copper carbonate; and at least 5 mg/ml selenium derived directly and/or indirectly from Na2SeO4 and/or Na2SeO3.

Abstract: A trace element solution comprises selenium, zinc, manganese and iron at a concentration of at least 60 mg/ml. The solution may further comprise at least one compound selected from the group comprising iodine, potassium iodide, sodium iodide, iron chloride, zinc oxide, manganese sulphate, sodium selenite, copper carbonate, sodium carbonate, anhydrous disodium EDTA and sodium hydroxide.

Abstract: In various embodiments, the present disclosure relates generally to gaming systems and methods providing a live craps game and a plurality of electronic gaming machines that facilitate participation in the live craps game.

Abstract: The present invention relates to combinations and pharmaceutical compositions comprising siponimod and laquinimod, and the use of said combinations and/or compositions for the treatment of multiple sclerosis, particularly secondary progressive multiple sclerosis.

Abstract: In various embodiments, the present disclosure relates generally to gaming systems and methods providing a live craps game and a plurality of electronic gaming machines that facilitate participation in the live craps game.